1-8 of 8
Natasha Greatorex
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Talha Munir, Abraham Mullasseril Varghese, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankara Paneesha, Christopher P Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, Prof. John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Anna Hockaday, David A. Cairns, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, David Stones, Nichola McWhirter, Surita Dalal, Andrew Rawstron, Piers Patten, Peter Hillmen
Journal: Blood
Blood (2024) 144 (Supplement 1): 585.
https://doi.org/10.1182/blood-2024-211449
Published: 2024
Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 632.
https://doi.org/10.1182/blood-2023-187943
Published: 2023
Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Surita Dalal, Anita Sarma, Jane Shingles, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4637.
https://doi.org/10.1182/blood-2023-180527
Published: 2023
Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David Allan Cairns, Adrian John Clifton Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankaranarayana Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M de Tute, Andrew Rawstron, Piers EM Patten, Talha Munir
Journal: Blood
Blood (2023) 142 (Supplement 1): 631.
https://doi.org/10.1182/blood-2023-178298
Published: 2023
Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Anita Sarma, Charlotte Evans, Surita Dalal, Nichola Webster, Andy Rawstron, Jane Shingles, Darren Newton, David Allan Cairns, Paul Glover, Thomas Grand, Helen Warren, Sue Bell, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4636.
https://doi.org/10.1182/blood-2023-188597
Published: 2023
Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Talha Munir, Alexandra Pitchford, Adrian Bloor, Andrew Pettitt, Piers E.M. Patten, Francesco Forconi, Anna Schuh, Christopher P Fox, Simona Gatto, Ben Kennedy, John Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Nichola McWhirter, Jane Shingles, Kate Cwynarski, Shankara Paneesha, David Allsup, Andrew Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 231–233.
https://doi.org/10.1182/blood-2022-170463
Published: 2022
Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Talha Munir, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Simona Gatto, Shankara Paneesha, Christopher P. Fox, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Piers EM Patten, David Allsup, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 2636.
https://doi.org/10.1182/blood-2021-152167
Published: 2021
Journal Articles

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha, Christopher P. Fox, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Piers EM Patten, David Allsup, Talha Munir
Journal: Blood
Blood (2021) 138 (Supplement 1): 642.
https://doi.org/10.1182/blood-2021-152319
Published: 2021